Will Clofazimine be included in medical insurance in 2025?

Clofazimine (Clofazimine) has a unique position in the global leprosy treatment system. Its core applications are mainly focused on three aspects: treating various types of leprosy, managing leprosy reactions, and as a backup drug for certain drug-resistant mycobacterial infections. In the multidrug treatment regimen for leprosy recommended by the World Health Organization, it has always been one of the important components of the triple regimen. It has been used for a long time because of its strong tissue accumulation ability, stable effect, and ability to reduce the risk of acquired drug resistance. For patients with recurrent erythematous nodular leprosy reactions or chronic leprosy reactions, clofazimine is regarded as a key drug to control recurrence of inflammation because of its antibacterial and immunomodulatory effects.

In the field of tuberculosis, although clofazimine shows some in vitro activity, its application is mainly limited to special programs for some multidrug-resistant tuberculosis due to its obvious side effects and numerous alternative drugs. It is usually decided by specialists whether to include it in treatment.

In terms of domestic launch status, the original research version of clofazimine has not yet been launched in China, but the domestic version has been approved and entered the medical insurance catalog. The domestic market specification is usually 50mg*10 tablets, and the price after medical insurance is about 500 yuan. The reimbursement ratio in different places will vary due to differences in medical insurance policies. It is recommended to refer to the actual price in the hospital pharmacy. The inclusion of clofazimine in medical insurance means that the accessibility of treatment for leprosy patients has been greatly improved, and the economic burden of long-term treatment has been substantially alleviated.

Taken together, the role of clofazimine in leprosy management is long-term and stable. After entering the medical insurance, it will help standardize treatment and improve patient compliance. Its use in China will also be more standardized and accessible in the future.

Reference materials:https://www.novartis.com/our-products/pipeline/clofazimine